Accedi

Bibliografie tematiche / Cystic fibrosis Gene therapy / Articoli di riviste

Segui questo link per vedere altri tipi di pubblicazioni sul tema: Cystic fibrosis Gene therapy.

Articoli di riviste sul tema "Cystic fibrosis Gene therapy"

Autore: Grafiati

Pubblicato: 4 giugno 2021

Ultima modifica: 11 febbraio 2022

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "Cystic fibrosis Gene therapy".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.

1

Griesenbach, Uta, Jane C. Davies e Eric Alton. "Cystic fibrosis gene therapy". Current Opinion in Pulmonary Medicine 22, n. 6 (novembre 2016): 602–9. http://dx.doi.org/10.1097/mcp.0000000000000327.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Colledge, W. H., e M. J. Evans. "Cystic fibrosis gene therapy". British Medical Bulletin 51, n. 1 (gennaio 1995): 82–90. http://dx.doi.org/10.1093/oxfordjournals.bmb.a072955.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Colledge, William H. "Cystic fibrosis gene therapy". Current Opinion in Genetics & Development 4, n. 3 (giugno 1994): 466–71. http://dx.doi.org/10.1016/0959-437x(94)90037-x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Prickett, Michelle, e Manu Jain. "Gene therapy in cystic fibrosis". Translational Research 161, n. 4 (aprile 2013): 255–64. http://dx.doi.org/10.1016/j.trsl.2012.12.001.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Colledge, WH. "Gene therapy for cystic fibrosis". Lancet 349, n. 9060 (aprile 1997): 1249. http://dx.doi.org/10.1016/s0140-6736(97)26017-4.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Dodge, J. A. "Gene therapy for cystic fibrosis". Nature Medicine 1, n. 3 (marzo 1995): 182. http://dx.doi.org/10.1038/nm0395-182a.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Armstrong, D. K., S. Cunningham, J. C. Davies e E. W. F. Alton. "Gene therapy in cystic fibrosis". Archives of Disease in Childhood 99, n. 5 (24 gennaio 2014): 465–68. http://dx.doi.org/10.1136/archdischild-2012-302158.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Wagner, MD, PhD, John A., e Phyllis Gardner, MD. "TOWARD CYSTIC FIBROSIS GENE THERAPY". Annual Review of Medicine 48, n. 1 (febbraio 1997): 203–16. http://dx.doi.org/10.1146/annurev.med.48.1.203.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Flotte, Terence R., e Beth L. Laube. "Gene Therapy in Cystic Fibrosis". Chest 120, n. 3 (settembre 2001): 124S—131S. http://dx.doi.org/10.1378/chest.120.3_suppl.124s.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Alton, Eric, Stephen Smith e Duncan Geddes. "Gene therapy for cystic fibrosis". Lancet 349, n. 9060 (aprile 1997): 1249–50. http://dx.doi.org/10.1016/s0140-6736(05)62441-5.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

11

Janet E Larson, Y., Susan L. Morrow e J. Craig Cohen. "Gene therapy for cystic fibrosis". Lancet 349, n. 9060 (aprile 1997): 1250. http://dx.doi.org/10.1016/s0140-6736(05)62442-7.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

12

Turner, Gillian. "Gene therapy for cystic fibrosis". Lancet 349, n. 9060 (aprile 1997): 1250–51. http://dx.doi.org/10.1016/s0140-6736(05)62443-9.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

13

Boyd, A. Christopher. "Gene therapy for cystic fibrosis". Expert Opinion on Therapeutic Patents 11, n. 1 (gennaio 2001): 1–15. http://dx.doi.org/10.1517/13543776.11.1.1.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

14

Boyd, A. Christopher. "Gene therapy for cystic fibrosis". Expert Opinion on Therapeutic Patents 11, n. 2 (febbraio 2001): 1–15. http://dx.doi.org/10.1517/13543776.11.2.1.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

15

Conese, Massimo, Sante Di Gioia e Stefano Castellani. "Gene therapy for cystic fibrosis". Expert Opinion on Therapeutic Patents 18, n. 8 (agosto 2008): 929–43. http://dx.doi.org/10.1517/13543776.18.8.929.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

16

Davies, Jane C., Duncan M. Geddes e Eric W. F. W. Alton. "Gene therapy for cystic fibrosis". Journal of Gene Medicine 3, n. 5 (2001): 409–17. http://dx.doi.org/10.1002/jgm.200.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

17

Bellon, G. "Cystic fibrosis (CF) gene therapy". Pediatric Pulmonology 23, S16 (aprile 1997): 278–79. http://dx.doi.org/10.1002/ppul.19502308144.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

18

Johnson, Larry G. "Gene Therapy for Cystic Fibrosis". Chest 107, n. 2 (febbraio 1995): 77S—83S. http://dx.doi.org/10.1378/chest.107.2_supplement.77s.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

19

Rosenfeld, Melissa A., e Francis S. Collins. "Gene Therapy for Cystic Fibrosis". Chest 109, n. 1 (gennaio 1996): 241–52. http://dx.doi.org/10.1378/chest.109.1.241.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

20

Coutelle, C., N. Caplen, S. Hart, C. Huxley e R. Williamson. "Gene therapy for cystic fibrosis." Archives of Disease in Childhood 68, n. 4 (1 aprile 1993): 437–40. http://dx.doi.org/10.1136/adc.68.4.437.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

21

Kitson, Chris, e Eric Alton. "Gene therapy for cystic fibrosis". Expert Opinion on Investigational Drugs 9, n. 7 (luglio 2000): 1523–35. http://dx.doi.org/10.1517/13543784.9.7.1523.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

22

Davies, J. C., e E. W. F. W. Alton. "Gene Therapy for Cystic Fibrosis". Proceedings of the American Thoracic Society 7, n. 6 (28 ottobre 2010): 408–14. http://dx.doi.org/10.1513/pats.201004-029aw.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

23

Luder, Elisabeth. "Gene Therapy for Cystic Fibrosis". Topics in Clinical Nutrition 14, n. 4 (settembre 1999): 22–30. http://dx.doi.org/10.1097/00008486-199909000-00004.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

24

Mueller, Christian, e Terence R. Flotte. "Gene Therapy for Cystic Fibrosis". Clinical Reviews in Allergy & Immunology 35, n. 3 (4 luglio 2008): 164–78. http://dx.doi.org/10.1007/s12016-008-8080-3.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

25

Alton, E. W. F. W. "Gene therapy for cystic fibrosis". Journal of Inherited Metabolic Disease 18, n. 4 (1995): 501–7. http://dx.doi.org/10.1007/bf00710061.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

26

Geddes, D. "Gene therapy for cystic fibrosis". Netherlands Journal of Medicine 46, n. 6 (giugno 1995): 306–12. http://dx.doi.org/10.1016/0300-2977(95)00024-h.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

27

Coutelle, Charles. "Gene therapy approaches for cystic fibrosis". Biologicals 23, n. 1 (marzo 1995): 21–25. http://dx.doi.org/10.1016/1045-1056(95)90006-3.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

28

Brown, Matt. "Gene therapy trials for cystic fibrosis". Drug Discovery Today 7, n. 15 (agosto 2002): 788–89. http://dx.doi.org/10.1016/s1359-6446(02)02393-0.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

29

Higgins, Christopher F., Stephen C. Hyde e Deborah R. Gill. "Towards Gene Therapy for Cystic Fibrosis". Biochemical Society Transactions 27, n. 5 (1 ottobre 1999): A137. http://dx.doi.org/10.1042/bst027a137a.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

30

ALTON, E. W. F. W. "Towards Gene Therapy For Cystic Fibrosis*". Journal of Pharmacy and Pharmacology 47, n. 5 (maggio 1995): 351–54. http://dx.doi.org/10.1111/j.2042-7158.1995.tb05809.x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

31

Ezzell, C. "Gene Therapy for Cystic Fibrosis Patients". Science News 142, n. 24 (12 dicembre 1992): 405. http://dx.doi.org/10.2307/4017870.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

32

O'Neal, WK, e AL Beaudet. "Somatic gene therapy for cystic fibrosis". Human Molecular Genetics 3, suppl_1 (1 settembre 1994): 1497–502. http://dx.doi.org/10.1093/hmg/3.suppl_1.1497.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

33

Griesenbach, Uta, Duncan M. Geddes e Eric W. F. W. Alton. "Advances in cystic fibrosis gene therapy". Current Opinion in Pulmonary Medicine 10, n. 6 (novembre 2004): 542–46. http://dx.doi.org/10.1097/01.mcp.0000142102.91202.04.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

34

Griesenbach, U., e E. W. F. W. Alton. "Moving forward: cystic fibrosis gene therapy". Human Molecular Genetics 22, R1 (4 agosto 2013): R52—R58. http://dx.doi.org/10.1093/hmg/ddt372.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

35

Parsons, DW. "Airway gene therapy and cystic fibrosis". Journal of Paediatrics and Child Health 41, n. 3 (marzo 2005): 94–96. http://dx.doi.org/10.1111/j.1440-1754.2005.00556.x.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

36

Wilson, James. "Cystic Fibrosis: Strategies for Gene Therapy". Seminars in Respiratory and Critical Care Medicine 15, n. 05 (settembre 1994): 439–45. http://dx.doi.org/10.1055/s-2007-1006389.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

37

Drittanti, L., MV Masciovecchio, J. Gabbarini e M. Vega. "Cystic fibrosis: gene therapy or preventive gene transfer?" Gene Therapy 4, n. 10 (ottobre 1997): 1001–3. http://dx.doi.org/10.1038/sj.gt.3300526.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

38

Kutsev, S. I., V. L. Izhevskaya e E. I. Kondratyeva. "Targeted therapy for cystic fibrosis". PULMONOLOGIYA 31, n. 2 (11 aprile 2021): 226–36. http://dx.doi.org/10.18093/0869-0189-2021-31-2-226-236.

Testo completo

Abstract (sommario):

The basic therapy of cystic fibrosis is currently aimed at slowing down the pathological processes associated with a decrease in the CFTR protein activity (cystic fibrosis transmembrane conductance regulator) in the gastrointestinal tract and the respiratory system. The pancreatic insufficiency is well compensated by replacement therapy with microsphere enzyme preparations and a high-calorie diet rich in proteins and fat. Chronic treatment of cystic fibrosis-related lung disease aims to improve the clearance of the bronchial tree, suppressing chronic bacterial infection and local chronic inflammation. However, no therapy was available to correct the defect in the gene or its product until 2012.The aim was to analyze literature on CFTR modulators, including their efficacy and safety, and assess the potential for developing new modulators to treat cystic fibrosis.Materials. The review included literature data (45 publications) on the use of CFTR modulators and international websites’ data.Results. Since the discovery of the CFTR gene in 1989, more than 2000 mutations or variants of the CFTR gene (hereinafter referred to as genetic variants) have been described. They interfere with the synthesis of the CFTR protein, its transport to the apical membrane of the cell, or disrupt its function as a channel for chloride anions. Although it is currently not possible to completely replace the mutant gene with a normal copy, small molecules have been identified that can modify the mutant CFTR protein and amend its function. The potential therapeutic measures are determined by class of the mutation. In clinical practice, pharmacological modeling of ion transport is currently possible only with the use of CFTR modulators: correctors and potentiators. The review defines these groups of drugs and describes 4 licensed CFTR modulators, including molecules of ivacaftor, lumacaftor, tezacaftor, elexacaftor. The data on the promising emerging next generation modulators and the prospects for the personalized selection of drugs using the assays on intestinal organoids are presented.

Gli stili APA, Harvard, Vancouver, ISO e altri

39

LEE, Tim W. R., David A. MATTHEWS e G. Eric BLAIR. "Novel molecular approaches to cystic fibrosis gene therapy". Biochemical Journal 387, n. 1 (22 marzo 2005): 1–15. http://dx.doi.org/10.1042/bj20041923.

Testo completo

Abstract (sommario):

Gene therapy holds promise for the treatment of a range of inherited diseases, such as cystic fibrosis. However, efficient delivery and expression of the therapeutic transgene at levels sufficient to result in phenotypic correction of cystic fibrosis pulmonary disease has proved elusive. There are many reasons for this lack of progress, both macroscopically in terms of airway defence mechanisms and at the molecular level with regard to effective cDNA delivery. This review of approaches to cystic fibrosis gene therapy covers these areas in detail and highlights recent progress in the field. For gene therapy to be effective in patients with cystic fibrosis, the cDNA encoding the cystic fibrosis transmembrane conductance regulator protein must be delivered effectively to the nucleus of the epithelial cells lining the bronchial tree within the lungs. Expression of the transgene must be maintained at adequate levels for the lifetime of the patient, either by repeat dosage of the vector or by targeting airway stem cells. Clinical trials of gene therapy for cystic fibrosis have demonstrated proof of principle, but gene expression has been limited to 30 days at best. Results suggest that viral vectors such as adenovirus and adeno-associated virus are unsuited to repeat dosing, as the immune response reduces the effectiveness of each subsequent dose. Nonviral approaches, such as cationic liposomes, appear more suited to repeat dosing, but have been less effective. Current work regarding non-viral gene delivery is now focused on understanding the mechanisms involved in cell entry, endosomal escape and nuclear import of the transgene. There is now increasing evidence to suggest that additional ligands that facilitate endosomal escape or contain a nuclear localization signal may enhance liposome-mediated gene delivery. Much progress in this area has been informed by advances in our understanding of the mechanisms by which viruses deliver their genomes to the nuclei of host cells.

Gli stili APA, Harvard, Vancouver, ISO e altri

40

Castellani, Stefano, e Massimo Conese. "Lentiviral Vectors and Cystic Fibrosis Gene Therapy". Viruses 2, n. 2 (29 gennaio 2010): 395–412. http://dx.doi.org/10.3390/v2020395.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

41

&NA;. "Is gene therapy for cystic fibrosis realistic?" Inpharma Weekly &NA;, n. 1137 (maggio 1998): 6. http://dx.doi.org/10.2165/00128413-199811370-00008.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

42

DAGANI, RON. "Big step toward cystic fibrosis gene therapy". Chemical & Engineering News 70, n. 3 (20 gennaio 1992): 6. http://dx.doi.org/10.1021/cen-v070n003.p006.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

43

Davies, Jane C. "Gene and cell therapy for cystic fibrosis". Paediatric Respiratory Reviews 7 (gennaio 2006): S163—S165. http://dx.doi.org/10.1016/j.prrv.2006.04.214.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

44

Tizzano, Eduardo F., e Manuel Buchwald. "Cystic fibrosis: Beyond the gene to therapy". Journal of Pediatrics 120, n. 3 (marzo 1992): 337–49. http://dx.doi.org/10.1016/s0022-3476(05)80895-9.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

45

Jaffe, A., A. Bush, D. M. Geddes e E. W. F. W. Alton. "Prospects for gene therapy in cystic fibrosis". Archives of Disease in Childhood 80, n. 3 (1 marzo 1999): 286–89. http://dx.doi.org/10.1136/adc.80.3.286.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

46

Alton, Eric WFW, e Duncan Geddes. "Gene Therapy: The Case for Cystic Fibrosis". Journal of the Royal Society of Medicine 90, n. 31_suppl (dicembre 1997): 43–46. http://dx.doi.org/10.1177/014107689709031s09.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

47

Caplen, Natasha J. "Cystic fibrosis gene therapy trials and tribulations". Trends in Molecular Medicine 7, n. 11 (novembre 2001): 488. http://dx.doi.org/10.1016/s1471-4914(01)02168-2.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

48

Davies, Jane C., Duncan M. Geddes e Eric W. F. W. Alton. "Prospects for gene therapy for cystic fibrosis". Molecular Medicine Today 4, n. 7 (luglio 1998): 292–99. http://dx.doi.org/10.1016/s1357-4310(98)01265-9.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

49

Fox, Jeffrey L. "NIHRAC okays gene therapy for cystic fibrosis". Nature Biotechnology 11, n. 1 (gennaio 1993): 29. http://dx.doi.org/10.1038/nbt0193-28b.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

50

Griesenbach, U., S. Ferrari, D. M. Geddes e E. W. F. W. Alton. "Gene Therapy Progress and Prospects: Cystic fibrosis". Gene Therapy 9, n. 20 (ottobre 2002): 1344–50. http://dx.doi.org/10.1038/sj.gt.3301791.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!